Caris Life Sciences Inc. (CAI) Next Earnings Date & Expected ±12.4% Move

Per the Roarable RQD rating, CAI scores 73 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 14 / 20. Per the Roarable RQD rating, this reflects ROIC of 4.4% and an FCF yield of 0.65%. For an investor, these are modest return-on-capital and cash-generation figures, meaning the business currently converts little of its capital and market value into free cash flow.
• Whale 13F Flow: 18 / 20. The strongest pillar, described as institutional accumulation and options positioning. This suggests sophisticated holders have been building positions, a supportive signal, though the underlying 13F detail is not itemized in the source data.
• Insider Conviction: 12 / 20. Based on SEC Form 4 and Congressional PTR cluster flow. This is a middling reading; insider activity is present but not a dominant bullish signal.
• Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 0.91 with notable sector sensitivity. A beta below 1 implies somewhat lower volatility than the broad market, which may appeal to investors seeking moderated swings, but the sector sensitivity caveat limits the score.
• Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 9.79, Piotroski F is 8 of 9, and Debt/Equity is 0.66. These are the strongest fundamental supports in the profile and indicate a sound balance-sheet posture.

Taken together, the investment case rests on institutional accumulation and a strong balance sheet, offset by thin cash returns and valuation that the source data flags as stretched (EV/EBITDA of 95). Valuation tradeoffs are significant: the stock trades at a forward P/E of 21 but carries negative trailing EPS of -0.24, so near-term earnings support depends on forecasts rather than realized results.

Caris Life Sciences Inc. is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the company profile. The profile identifies the company's market capitalization as $10.2B. The source data does not describe the company's products, customers, or revenue model.

Per the SEC financials, revenue grew from $306.1M (FY 2023) to $812.0M (FY 2025), and operating income moved from a loss to $45.1M in FY 2025, though FY 2025 net income remained negative at $-68.1M. Per the market data, operating margin is 5.6% and net margin is -8.4%. ROIC is 4.4%. Per the Roarable RQD rating, the Altman Z-Score is 9.79, the Piotroski F-Score is 8 of 9, and Debt/Equity is 0.66, indicating a strong balance-sheet posture. Reported debt declined from $1314.4M in FY 2023 to $378.8M in FY 2025.

Six headlines reference CAI. Per the recent news feed, a TradingView item reports a 12-month price target raised to $30.23 implying 10% upside, tagged as a green catalyst. A MarketBeat item reports a price target raised at JPMorgan Chase & Co., also tagged green. Other items, including Simply Wall St, MarketBeat ("Shares Up 7.6%"), and Stock Titan, are tagged yellow as market-wire coverage. Risk watch items are not separately identified in the source data. The Butterfly Supply-Chain Graph lists no proprietary signals.

• What products and customers generate the FY 2025 revenue of $812.0M, and what drove the swing to positive operating income?
• Why is trailing P/E unavailable while forward P/E is 21, and what earnings path underlies that forecast?
• What specific institutional holders and options positions underlie the 18/20 whale-flow score?
• Which insider transactions drive the 12/20 insider conviction score, and over what timeframe?
• What explains the EV/EBITDA of 95 relative to the 4.4% ROIC and 0.65% FCF yield?